Studies on platelet aggregation inhibitors in vivo. X. Relationship to thrombolysis.
Human labeled fibrin clots were inserted into femoral veins of stumptailed monkeys (Macaca arctoides). Thrombolysis was slightly increased by treatment with the platelet aggregation inhibitor pentoxifylline. This agent significantly potentiated the thrombolytic effect of urokinase activated human plasminogen. Pentoxifylline was also found to release plasminogen activator activity into the circulation.
D000818:Animals; D003864:Depression, Chemical; D004357:Drug Synergism; D005341:Fibrinolysin / Q000494:pharmacology; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008251:Macaca; D008297:Male; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D013805:Theobromine / Q000031:analogs & derivatives*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D005343:Fibrinolytic Agents; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; D013805:Theobromine; D010431:Pentoxifylline